Laboratorios Farmaceuticos Rovi (ROVI) Stock Statistics & Valuation Metrics

Laboratorios Farmaceuticos Rovi has a market cap or net worth of €2.68B. The enterprise value is €2.86B.

Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.

Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 19.73%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 763.75M and earned 136.88M in profits. Earnings per share was 2.67.

In the last 12 months, operating cash flow was 141.58M and capital expenditures -61.50M, giving a free cash flow of 80.08M billion.

Laboratorios Farmaceuticos Rovi pays an annual dividend of €0.935, resulting in a dividend yield of 1.72%

Laboratorios Farmaceuticos Rovi upcoming earnings date is Nov 6, 2025, TBA (Confirmed).

Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 18.37%

In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 40.81M in taxes.

Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 15.96, with an EV/FCF ratio of 43.58.

Laboratorios Farmaceuticos Rovi has €29.31M in cash and marketable securities with €108.38M in debt, giving a net cash position of €79.08M billion.

Gross margin is 64.46%, with operating margin of 23.51%, and net profit margin of 17.92%.

The average price target for Laboratorios Farmaceuticos Rovi is €90.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy